### Artemether + lumefantrine

**Indication:** Malaria due to *Plasmodium falciparum*

**INN:** Artemether + lumefantrine

**Medicine type:** Chemical agent

**List type:** Core (EML) (EMLc)

**Additional notes:** Not recommended in the first trimester of pregnancy or in children below 5 kg

**Formulations:** Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet (EMLc)

**EML status history:**
- First added in 2002 (TRS 914)
- Changed in 2007 (TRS 946)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)

**Sex:** All

**Age:** Also recommended for children

**Weight restriction:** Children > 5 kg

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

**Wikipedia:** [Artemether + lumefantrine](https://en.wikipedia.org/wiki/Artemether_lumefantrine)

**DrugBank:** [Artemether](https://www.drugbank.ca/drugs/DB00577), [Lumefantrine](https://www.drugbank.ca/drugs/DB00578)

---

**Summary of evidence and Expert Committee recommendations**

Artemether + lumefantrine dispersible tablet formulation was added for children use in the treatment of malaria.